key: cord-0995944-dvl13ube authors: Davis, John W. title: BJUI Compass 2021 year‐end review date: 2021-11-17 journal: BJUI Compass DOI: 10.1002/bco2.122 sha: 3743f55be40d3ab728c437d06da43b1469db1a97 doc_id: 995944 cord_uid: dvl13ube nan pandemic, and a number of articles are now available on the effect of the pandemic on urologic practice. Our initial issues had at least four articles/issue, and this past year, we are at around eight/issue. Overall, we had 71 submissions in 2020 and this year on pace for 90. In conclusion, it has been a satisfying growth trend for BJUI Compass. We look forward to furthering the science in our field in 2022. In the meantime, Figure 1 shows a glimmer of hope regarding in-person events post pandemic. poor, but they noted that sites that listed specific certifications or benchmarks did better. If you are asked to help your hospital with patient level online information, this paper may provide effective guidance. Touching upon the topics of COVID-19 and prostate cancer treatment, Barrett Orthotopic bladder substitution: surgical aspects and optimization of outcomes Performance of prostate health index and PSA density in a diverse biopsy-naïve cohort with mpMRI for detecting significant prostate cancer The utility of magnetic resonance imaging in prostate cancer diagnosis in the Australian setting Nurse-led one stop hematuria clinic: outcomes from 2,714 patients. BJUI Compass Transperineal prostate biopsy identifies locations of clinically significant prostate cancer in men considering focal therapy with PI-RADS 3-5 regions of interest Systematic expression analysis of m6A RNA methyltransferases in clear cell renal cell carcinoma Quality and readability of online patient information on treatment for erectile dysfunction Gonadorelins adherence in prostate cancer: a time-series analysis of England's national prescriptions during the COVID-19 pandemic Local versus general anesthesia transperineal prostate biopsy: tolerability, cancer detection, and complications. BJUI Compass